Patient and Health Care Professional Perspectives on the Burden and Daily Life Impact of Ulcerative Colitis and Crohn’s Disease: Results from the Japanese CONFIDE Study

IF 4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Advances in Therapy Pub Date : 2025-02-28 DOI:10.1007/s12325-024-03078-3

Toshifumi Hibi, Taku Kobayashi, Masaru Tanaka, Satoshi Osaga, Alison J. Potts Bleakman, Theresa Hunter Gibble, Marijana Nedeljkovic Protic, Isabel Redondo, Koji Matsuo, Tadakazu Hisamatsu

{"title":"Patient and Health Care Professional Perspectives on the Burden and Daily Life Impact of Ulcerative Colitis and Crohn’s Disease: Results from the Japanese CONFIDE Study","authors":"Toshifumi Hibi, Taku Kobayashi, Masaru Tanaka, Satoshi Osaga, Alison J. Potts Bleakman, Theresa Hunter Gibble, Marijana Nedeljkovic Protic, Isabel Redondo, Koji Matsuo, Tadakazu Hisamatsu","doi":"10.1007/s12325-024-03078-3","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>The global Communicating Needs and Features of Inflammatory Bowel Disease Experiences (CONFIDE) study aimed to evaluate the impact of ulcerative colitis (UC)- and Crohn’s disease (CD)-related symptoms on patients’ lives and elucidate communication gaps between patients and health care professionals (HCPs). We report the findings from the study in patients with UC or CD and HCPs in Japan.</p><h3>Methods</h3><p>Online, quantitative, cross-sectional surveys were conducted in Japan for patients with moderate-to-severe UC or CD and HCPs responsible for the care of patients with UC and/or CD. Subgroup analyses based on disease activity were conducted using the Manitoba Inflammatory Bowel Disease Index. Data were described using descriptive statistics.</p><h3>Results</h3><p>Surveys were completed by 124 patients with UC, 99 patients with CD, and 100 HCPs in Japan. Differences were noted in the most common patient-reported symptoms experienced in the month prior to survey completion between patients with UC and CD (diarrhea [45.2% UC, 68.7% CD], flatulence [34.7% UC, 32.3% CD], increased stool frequency [32.3% UC, 43.4% CD], bowel urgency [BU; 25.0% UC, 32.3% CD], and fatigue [36.4% CD]). More patients with active disease than inactive disease reported these symptoms. BU and BU-related accidents were among the symptoms ranked as most impactful by patients with UC and CD. HCP-perceived symptoms with the greatest impact on patients were diarrhea and blood in stool. Findings in the Japanese cohort of CONFIDE were generally consistent with those in the United States (US)/European cohorts. The percentage of patients reporting BU as the symptom with the greatest impact was higher in the US/European cohorts than in the Japanese cohort, potentially as a result of differences in baseline characteristics and social environments such as toilet facilities.</p><h3>Conclusion</h3><p>BU is an impactful symptom among Japanese patients with UC and CD and should be considered by HCPs during treatment of these conditions.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 4","pages":"1834 - 1859"},"PeriodicalIF":4.0000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-024-03078-3.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-024-03078-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

The global Communicating Needs and Features of Inflammatory Bowel Disease Experiences (CONFIDE) study aimed to evaluate the impact of ulcerative colitis (UC)- and Crohn’s disease (CD)-related symptoms on patients’ lives and elucidate communication gaps between patients and health care professionals (HCPs). We report the findings from the study in patients with UC or CD and HCPs in Japan.

Methods

Online, quantitative, cross-sectional surveys were conducted in Japan for patients with moderate-to-severe UC or CD and HCPs responsible for the care of patients with UC and/or CD. Subgroup analyses based on disease activity were conducted using the Manitoba Inflammatory Bowel Disease Index. Data were described using descriptive statistics.

Results

Surveys were completed by 124 patients with UC, 99 patients with CD, and 100 HCPs in Japan. Differences were noted in the most common patient-reported symptoms experienced in the month prior to survey completion between patients with UC and CD (diarrhea [45.2% UC, 68.7% CD], flatulence [34.7% UC, 32.3% CD], increased stool frequency [32.3% UC, 43.4% CD], bowel urgency [BU; 25.0% UC, 32.3% CD], and fatigue [36.4% CD]). More patients with active disease than inactive disease reported these symptoms. BU and BU-related accidents were among the symptoms ranked as most impactful by patients with UC and CD. HCP-perceived symptoms with the greatest impact on patients were diarrhea and blood in stool. Findings in the Japanese cohort of CONFIDE were generally consistent with those in the United States (US)/European cohorts. The percentage of patients reporting BU as the symptom with the greatest impact was higher in the US/European cohorts than in the Japanese cohort, potentially as a result of differences in baseline characteristics and social environments such as toilet facilities.

Conclusion

BU is an impactful symptom among Japanese patients with UC and CD and should be considered by HCPs during treatment of these conditions.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

患者和卫生保健专业人员对溃疡性结肠炎和克罗恩病负担和日常生活影响的看法：来自日本CONFIDE研究的结果

简介：全球炎症性肠病经历的沟通需求和特征（CONFIDE）研究旨在评估溃疡性结肠炎（UC）和克罗恩病（CD）相关症状对患者生活的影响，并阐明患者与卫生保健专业人员（HCPs）之间的沟通差距。我们报告了日本UC或CD和HCPs患者的研究结果。方法：在日本对中重度UC或CD患者和负责UC和/或CD患者护理的HCPs进行在线、定量、横断面调查。使用马尼托巴炎症性肠病指数进行基于疾病活动性的亚组分析。数据采用描述性统计进行描述。结果：日本124名UC患者、99名CD患者和100名HCPs患者完成了调查。在调查结束前一个月内，UC和CD患者最常见的症状(腹泻[45.2% UC, 68.7% CD]，肠胃胀气[34.7% UC, 32.3% CD]，大便频率增加[32.3% UC, 43.4% CD]，肠急症[BU；25.0% UC， 32.3% CD]和疲劳[36.4% CD])。活动性疾病患者比非活动性疾病患者更多地报告了这些症状。溃疡性结肠炎和乳糜泻患者认为影响最大的症状是溃疡性结肠炎和溃疡性结肠炎相关事故。hcp认为对患者影响最大的症状是腹泻和便血。CONFIDE的日本队列研究结果与美国/欧洲队列研究结果基本一致。在美国/欧洲队列中，报告布鲁里溃疡为影响最大症状的患者比例高于日本队列，这可能是由于基线特征和社会环境（如厕所设施）的差异。结论：在日本UC和CD患者中，BU是一种有影响的症状，HCPs在治疗这些疾病时应予以考虑。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.